Cargando…
Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma
PURPOSE: Management of adult soft tissue sarcomas entails a multidisciplinary approach with surgery and radiation therapy with or without chemotherapy. The use of preoperative irradiation has been well established, and although conventional fractionation involves daily treatments over the course of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133395/ https://www.ncbi.nlm.nih.gov/pubmed/35647402 http://dx.doi.org/10.1016/j.adro.2021.100850 |
_version_ | 1784713556576436224 |
---|---|
author | Bedi, Meena Singh, Reena Charlson, John A. Kelly, Tracy Johnstone, Candice Wooldridge, Adam Hackbarth, Donald A. Moore, Nicole Neilson, John C. King, David M. |
author_facet | Bedi, Meena Singh, Reena Charlson, John A. Kelly, Tracy Johnstone, Candice Wooldridge, Adam Hackbarth, Donald A. Moore, Nicole Neilson, John C. King, David M. |
author_sort | Bedi, Meena |
collection | PubMed |
description | PURPOSE: Management of adult soft tissue sarcomas entails a multidisciplinary approach with surgery and radiation therapy with or without chemotherapy. The use of preoperative irradiation has been well established, and although conventional fractionation involves daily treatments over the course of 5 weeks, higher doses per fraction may be beneficial due to the radiobiologic profile of sarcoma. In this study we report long-term oncologic outcomes from a single-institution, phase II study evaluating a 5-fraction hypofractionated course of preoperative radiation. METHODS AND MATERIALS: Preoperative hypofractionated radiation therapy was administered to 35 Gy in 5 fractions every other day followed by resection 4 to 6 weeks later. If given, chemotherapy consisted of a doxorubicin-ifosfamide-based regimen delivered neoadjuvantly. The primary endpoint was local control. Additional survival and pathologic outcomes, including overall and distant metastasis-free survival, tumor, and treatment-related pathology, as well as acute and late toxicity were examined. RESULTS: Thirty-two patients were enrolled in this prospective, single-arm phase II trial. At a median follow-up of 36.4 months (range, 3-56), no patient developed a local recurrence, and the 3-year overall and distant metastasis-free survival was 82.2% and 69%, respectively. Major acute postoperative wound complications occurred in 25% of patients. Grade 2 and 3 fibrosis occurred in 21.7% and 13% of patients, respectively. The 2-year median and mean Musculoskeletal Tumor Society score for all patients was 28 and 27.4, respectively. CONCLUSIONS: A condensed course of preoperative hypofractionated radiation therapy leads to excellent rates of local control and survival with acceptable toxicity profiles. Potential studies ideally with phase II or III randomized trials would help corroborate these findings and other preoperative hypofractionated results in soft tissue sarcomas. |
format | Online Article Text |
id | pubmed-9133395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91333952022-05-27 Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma Bedi, Meena Singh, Reena Charlson, John A. Kelly, Tracy Johnstone, Candice Wooldridge, Adam Hackbarth, Donald A. Moore, Nicole Neilson, John C. King, David M. Adv Radiat Oncol Scientific Article PURPOSE: Management of adult soft tissue sarcomas entails a multidisciplinary approach with surgery and radiation therapy with or without chemotherapy. The use of preoperative irradiation has been well established, and although conventional fractionation involves daily treatments over the course of 5 weeks, higher doses per fraction may be beneficial due to the radiobiologic profile of sarcoma. In this study we report long-term oncologic outcomes from a single-institution, phase II study evaluating a 5-fraction hypofractionated course of preoperative radiation. METHODS AND MATERIALS: Preoperative hypofractionated radiation therapy was administered to 35 Gy in 5 fractions every other day followed by resection 4 to 6 weeks later. If given, chemotherapy consisted of a doxorubicin-ifosfamide-based regimen delivered neoadjuvantly. The primary endpoint was local control. Additional survival and pathologic outcomes, including overall and distant metastasis-free survival, tumor, and treatment-related pathology, as well as acute and late toxicity were examined. RESULTS: Thirty-two patients were enrolled in this prospective, single-arm phase II trial. At a median follow-up of 36.4 months (range, 3-56), no patient developed a local recurrence, and the 3-year overall and distant metastasis-free survival was 82.2% and 69%, respectively. Major acute postoperative wound complications occurred in 25% of patients. Grade 2 and 3 fibrosis occurred in 21.7% and 13% of patients, respectively. The 2-year median and mean Musculoskeletal Tumor Society score for all patients was 28 and 27.4, respectively. CONCLUSIONS: A condensed course of preoperative hypofractionated radiation therapy leads to excellent rates of local control and survival with acceptable toxicity profiles. Potential studies ideally with phase II or III randomized trials would help corroborate these findings and other preoperative hypofractionated results in soft tissue sarcomas. Elsevier 2022-01-25 /pmc/articles/PMC9133395/ /pubmed/35647402 http://dx.doi.org/10.1016/j.adro.2021.100850 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Scientific Article Bedi, Meena Singh, Reena Charlson, John A. Kelly, Tracy Johnstone, Candice Wooldridge, Adam Hackbarth, Donald A. Moore, Nicole Neilson, John C. King, David M. Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma |
title | Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma |
title_full | Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma |
title_fullStr | Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma |
title_full_unstemmed | Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma |
title_short | Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma |
title_sort | is 5 the new 25? long-term oncologic outcomes from a phase ii, prospective, 5-fraction preoperative radiation therapy trial in patients with localized soft tissue sarcoma |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133395/ https://www.ncbi.nlm.nih.gov/pubmed/35647402 http://dx.doi.org/10.1016/j.adro.2021.100850 |
work_keys_str_mv | AT bedimeena is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT singhreena is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT charlsonjohna is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT kellytracy is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT johnstonecandice is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT wooldridgeadam is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT hackbarthdonalda is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT moorenicole is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT neilsonjohnc is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma AT kingdavidm is5thenew25longtermoncologicoutcomesfromaphaseiiprospective5fractionpreoperativeradiationtherapytrialinpatientswithlocalizedsofttissuesarcoma |